News

MPS IIIA, a rare metabolic disorder also known as Sanfilippo syndrome type A, affects children from an early age. The condition results in severe deterioration of the central nervous

Under the deal, Celgene will purchase Juno’s stock by paying $87 per share in cash. Juno is engaged in the development of novel cellular immunotherapies for the treatment

The EC approval marks Bristol-Myers Squibb’s first pediatric indication for an Immuno-Oncology medicine in the European Union (EU) and allows for the marketing of Yervoy for this indication

Under the terms of the agreement Abcam will obtain the exclusive rights to the product portfolio of Spring Bioscience Corporation in the research use only (RUO) field of

Bioverativ, which is a spin-off from biotech firm Biogen, focuses on therapies for hemophilia and other rare blood disorders. As per the merger deal terms, Sanofi will start

The sBLA was submitted by Genmab’s licensing partner, Janssen Biotech, Inc., in November 2017. Priority Review is an FDA designation for drugs that treat a serious condition and

SymBio holds approval for TREAKISYM injectables which are already used for the treatment of three indications of malignant lymphoma (first-line and relapsed/refractory low-grade B-cell non-Hodgkin's lymphoma and mantle

Lynparza has been approved as a maintenance treatment for patients in whom ovarian cancer had relapsed, and are sensitive to platinum chemotherapy. The approval for the treatment is

Final patient data from the trial are being collated and entered into the database, checked and analysed. This process is ongoing and top line results remain on track